How to buy Intra-Cellular Therapies (ITCI) stock

Intra-Cellular Therapies, Inc is a biotechnology business based in the US. Intra-Cellular Therapies shares (ITCI) are listed on the NASDAQ and all prices are listed in US Dollars. Intra-Cellular Therapies employs 383 staff and has a trailing 12-month revenue of around 0.00.

Intra-Cellular Therapies stock price (NASDAQ: ITCI)

Use our graph to track the performance of ITCI stocks over time.

Intra-Cellular Therapies shares at a glance

• Key figures

Information last updated 2021-07-22.

Latest market close	$39.41
52-week range	$17.26 - $44.80
50-day moving average	$40.86
200-day moving average	$36.20
Wall St. target price	$52.13
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-2.81

Buy Intra-Cellular Therapies shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Intra-Cellular Therapies stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Intra-Cellular Therapies, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Intra-Cellular Therapies price performance over time

Historical closes compared with the close of $39.41 from 2021-05-28

1 week (2021-07-14)	N/A
1 month (2021-06-25)	-5.04%
3 months (2021-04-21)	N/A
6 months (2021-01-21)	N/A

1 year (2020-07-21)	N/A
2 years (2019-07-21)	N/A
3 years (2018-07-21)	N/A
5 years (2016-07-21)	N/A

Intra-Cellular Therapies financials

Revenue TTM	$37.6 million
Gross profit TTM	$-44,864,187
Return on assets TTM	-25.46%
Return on equity TTM	-44.57%
Profit margin	0%
Book value	$7.55
Market capitalisation	$3 billion

TTM: trailing 12 months

Shorting Intra-Cellular Therapies shares

There are currently 5.2 million Intra-Cellular Therapies shares held short by investors – that's known as Intra-Cellular Therapies's "short interest". This figure is 12.3% down from 5.9 million last month.

There are a few different ways that this level of interest in shorting Intra-Cellular Therapies shares can be evaluated.

Intra-Cellular Therapies's "short interest ratio" (SIR)

Intra-Cellular Therapies's "short interest ratio" (SIR) is the quantity of Intra-Cellular Therapies shares currently shorted divided by the average quantity of Intra-Cellular Therapies shares traded daily (recently around 594742.80782509). Intra-Cellular Therapies's SIR currently stands at 8.69. In other words for every 100,000 Intra-Cellular Therapies shares traded daily on the market, roughly 8690 shares are currently held short.

However Intra-Cellular Therapies's short interest can also be evaluated against the total number of Intra-Cellular Therapies shares, or, against the total number of tradable Intra-Cellular Therapies shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Intra-Cellular Therapies's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Intra-Cellular Therapies shares in existence, roughly 60 shares are currently held short) or 0.0698% of the tradable shares (for every 100,000 tradable Intra-Cellular Therapies shares, roughly 70 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Intra-Cellular Therapies.

Find out more about how you can short Intra-Cellular Therapies stock.

Intra-Cellular Therapies share dividends

We're not expecting Intra-Cellular Therapies to pay a dividend over the next 12 months.

Intra-Cellular Therapies share price volatility

Over the last 12 months, Intra-Cellular Therapies's shares have ranged in value from as little as $17.26 up to $44.8. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Intra-Cellular Therapies's is 1.3134. This would suggest that Intra-Cellular Therapies's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Intra-Cellular Therapies overview

Intra-Cellular Therapies, Inc. , a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also developing lumateperone, which is in Phase 3 clinical trials for the treatment of bipolar depression, as well as to treat autism spectrum disorder, and sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for the treatment of Parkinson's disease and heart failure; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.

Frequently asked questions

What percentage of Intra-Cellular Therapies is owned by insiders or institutions?
Currently 4.954% of Intra-Cellular Therapies shares are held by insiders and 91.102% by institutions. How many people work for Intra-Cellular Therapies?
Latest data suggests 383 work at Intra-Cellular Therapies. When does the fiscal year end for Intra-Cellular Therapies?
Intra-Cellular Therapies's fiscal year ends in December. Where is Intra-Cellular Therapies based?
Intra-Cellular Therapies's address is: 430 East 29th Street, New York, NY, United States, 10016 What is Intra-Cellular Therapies's ISIN number?
Intra-Cellular Therapies's international securities identification number is: US46116X1019 What is Intra-Cellular Therapies's CUSIP number?
Intra-Cellular Therapies's Committee on Uniform Securities Identification Procedures number is: 46116X101